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Peripheral neuropathy is a neurological condition that
commonly presents to the practicing podiatrist. Tradi-
tionally when sensory neuropathy is present one
assumes diabetes mellitus to be the contributing aetiol-
ogy. However, this is not always the case. Other com-
mon causes such as spinal damage, alcoholism, and
vitamin B12 deficiency can be precipitating aetiologies
that the clinician would be aware. 26% of individuals
over 65 years of age (without a predisposing disease
known to cause neuropathy) will develop peripheral
neuropathy at some point in life. What does the clini-
cian do when none of the common causes are present?
One clinical presentation tested this predicament. A
female patient presented with diagnosed statin induced
sensory peripheral neuropathy. This uncommon aetiol-
ogy lead to a literature search relating to the less com-
mon causes of peripheral neuropathy. There are
reported cases of statin induced peripheral neuropathy,
which in the initial stages can be reversible. Accumulat-
ing this research is difficult due to the wide variances in
results and study methods; proving further independent
research is needed. The reported incidence rate of per-
ipheral neuropathy ranges between 4-14 times more
likely for those on statins compared to control groups.
This case study will help to raise the profile of this
aetiology with the aim to preventing misdiagnosis. Inter-
estingly, the quality of life and political implications of
statin induced peripheral neuropathy are an aspect not
commonly considered. What was the eventual outcome
and how was the patient’s quality of life affected? The
patient now suffers from an irreversible peripheral neu-
ropathy. Thus, the patient is now exposed to the com-
plications of peripheral neuropathy, including shoe wear
and hosiery changes, daily foot checks, pressure area
development, and possibility of future neuropathic
ulceration. Could the outcome of peripheral neuropathy
have been changed if podiatry was involved earlier in
the patient’s management? The early detection of per-
ipheral neuropathy may have lead to a change in specific
medication to a statin that is not associated with periph-
eral neuropathy, therefore preventing the irreversible
damage. It should be asked was this patient managed
appropriately? Without the statins the patient would be
at risk of hypercholesterolemia, therefore increasing car-
diovascular risks such as acute myocardial infarction.
Diet and exercise modifications can have great effect
with lowering serum cholesterol. Such modifications
should be the initial treatment, or should be utilised in
conjunction with pharmacological intervention. Statins
should be used to lower serum cholesterol levels when
unable to do so with dietary modifications. However,
there are alternative statins available which do not con-
tain the same side effects (peripheral neuropathy) as
others within the class. So the drug of choice should be
made critically. Often medication is the first line treat-
ment option due to patient compliance and ease of
medical practitioner review. But it needs to be asked,
who would be liable if the patient was to ulcerate and
progressed to amputation? The patient, medical practi-
tioner, or podiatrist?
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